The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
